<PAGE> 1
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
Filed by the registrant [X]
Filed by a party other than the registrant [ ]
Check the appropriate box:
[ ] Preliminary proxy statement. [ ] Confidential, for use of the
Commission only (as permitted by
Rule 14a-6(e)(2)).
[ ] Definitive proxy statement.
[X] Definitive additional materials.
[ ] Soliciting material pursuant to Rule 14a-11(c) or Rule 14a-12.
Northfield Laboratories Inc.
--------------------------------------------------------------------------------
(Name of Registrant as Specified in Its Charter)
--------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of filing fee (check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
(1) Title of each class of securities to which transaction applies:
--------------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
--------------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
--------------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
--------------------------------------------------------------------------------
(5) Total fee paid:
--------------------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
--------------------------------------------------------------------------------
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the form or schedule and the date of its filing.
(1) Amount Previously Paid:
--------------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
--------------------------------------------------------------------------------
(3) Filing Party:
--------------------------------------------------------------------------------
(4) Date Filed:
--------------------------------------------------------------------------------
<PAGE> 2
NORTHFIELD LABORATORIES INC.
1560 SHERMAN AVENUE, SUITE 1000
EVANSTON, IL 60201
(847) 864-3500
WWW.NORTHFIELDLABS.COM
AT NORTHFIELD LABORATORIES: AT THE FINANCIAL RELATIONS BOARD:
Richard DeWoskin General Information
Chief Executive Officer Leslie Hunziker
(847) 864-3500 (312) 266-7800
FOR IMMEDIATE RELEASE
MONDAY, OCTOBER 9, 2000
NORTHFIELD LABORATORIES 2000 ANNUAL MEETING THIS WEEK;
BUSINESS UPDATE ACCESSIBLE ONLINE
Evanston, Illinois, October 9, 2000 -- Northfield Laboratories Inc. (Nasdaq/NMS:
NFLD), a leading developer of an oxygen-carrying blood substitute for trauma and
elective surgery applications, will host its annual meeting this Thursday,
October 12, 2000, at 9:00 a.m. Central Time. Following the business matters
described in Northfield's proxy material, a discussion of the company's
performance and prospects will be held online at 10:00 a.m.
Access to this presentation will only be available electronically or by
telephone. Interested parties may log on to www.vcall.com or
www.northfieldlabs.com at the designated time. The toll-free conference call
dial-in number is 800-982-3654 for those wishing to listen via telephone. The
online conference will allow shareholders to simultaneously receive an update on
the company and access to management's remarks.
Northfield Laboratories was founded in 1985. The company is headquartered in
Evanston, Illinois, and its stock is traded on the Nasdaq National Market System
under the symbol NFLD.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks, which may cause the
company's actual results in the future to differ materially from expected
results. These risks include, among others: competition from other blood
substitute products; the company's ability to obtain regulatory approval to
market PolyHeme commercially; the company's ability to successfully market and
sell PolyHeme; the company's ability to manufacture PolyHeme in sufficient
quantities; the company's ability to obtain an adequate supply of raw materials;
the company's ability
-more-
<PAGE> 3
Northfield Laboratories Inc.
Add 1
to maintain intellectual property protection for its proprietary product and to
defend its existing intellectual property rights from challenges by third
parties; the availability of capital to finance planned growth; and the extent
to which the hospitals and physicians using PolyHeme are able to obtain
third-party reimbursement, as described in the company's filing with the
Securities and Exchange Commission.
FOR MORE INFORMATION ON NORTHFIELD LABORATORIES INC. VIA FACSIMILE AT NO COST,
SIMPLY DIAL 1-800-PRO-INFO AND ENTER THE COMPANY CODE NFLD.
VISIT THE NORTHFIELD WEBSITE AT: WWW.NORTHFIELDLABS.COM
<PAGE> 4
2000 ANNUAL MEETING OF SHAREHOLDERS
Northfield Laboratories' annual meeting will take place on October 12, 2000, at
9:00 a.m. Central Time. This meeting is held strictly for the purpose of voting
on the matters described in Northfield's proxy material.
Separately, at 10:00 a.m. the same day, a discussion of the company's
performance and prospects will be held online. Access to this presentation will
only be available electronically or by telephone. Interested parties may log on
to www.vcall.com or www.northfieldlabs.com at the designated time. The
toll-free conference call dial-in number is 800-982-3654 for those wishing to
listen via telephone. The online conference will allow shareholders to
simultaneously receive an update on the company and access to management's
remarks. Questions for the question-and-answer session should be submitted in
writing or via electronic mail during the period leading up to the annual
meeting. Please email all questions to [email protected], or mail inquiries
to Investor Relations at the company's address.
